Related Experiment Video
Updated: May 5, 2026
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Small Molecule Agonists of TREM2 Reprogram Microglia and Protect Synapses in Human Alzheimer's Models
Abstract:
Triggering receptor expressed on myeloid cells-2 (TREM2) is a key immune receptor in the central nervous system that regulates microglial phagocytosis, survival, and neuroinflammatory responses. TRME2 variants have been established as genetic risk factors for Alzheimer's disease (AD). However, the therapeutic development of TREM2 modulators has been limited to antibody-based approaches that face limitations in blood-brain barrier penetration and manufacturing scalability. Furthermore, there are no FDA approved TREM2 therapeutics available to date marking an unmet therapeutic gap. Herein, we report the identification of the first TREM2 small molecule submicromolar binders as a result of optimizing compound 4a to yield S9 with TREM2 binding affinity of 0.95 µM. S9 demonstrated robust TREM2 agonism in cellular assays where it induced proximal Syk phosphorylation, activated downstream NFAT transcriptional signaling, enhanced APOE internalization and microglial phagocytic capacity. Pharmacokinetic profiling of the optimized hits revealed S9 to exhibit improved drug-likeness compared to 4a with 7-fold enhanced aqueous solubility, superior metabolic stability, reduced intrinsic clearance and a 9-fold improved hERG safety margin. Functional validation in human iPSC-derived microglia confirmed that S9 suppresses amyloid-beta (Aβ)-induced IL-1β secretion through a TREM2-dependent mechanism. In human neuron-microglia co-culture models exposed to amyloid stress, S9 treatment preserved synaptic integrity as measured by PSD95 expression that indicates promising neuroprotective activity. Together, these findings establish S9 as a first-TREM2 submicromolar small molecule TREM2 agonist which is orally bioavailable with favorable pharmacokinetic properties and promising therapeutic potential for the treatment of Alzheimer's disease.
Insights
Researchers developed S9, the first small molecule TREM2 agonist for Alzheimer's disease. This orally available drug shows promise in preclinical models by enhancing microglial function and protecting neurons.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Triggering receptor expressed on myeloid cells-2 (TREM2) is crucial for microglial function in the central nervous system.
- TREM2 variants are genetic risk factors for Alzheimer's disease (AD), highlighting TREM2 as a therapeutic target.
- Current TREM2 therapeutic strategies, primarily antibodies, face challenges with blood-brain barrier penetration and scalability.
Purpose of the Study:
- To identify and characterize novel small molecule agonists targeting TREM2 for potential Alzheimer's disease therapy.
- To optimize lead compounds for improved binding affinity, pharmacokinetic properties, and drug-likeness.
- To evaluate the therapeutic potential of the lead compound in cellular and co-culture models of AD.
Main Methods:
- Lead optimization of a TREM2 binder (compound 4a) to yield S9 with submicromolar affinity.
- In vitro assays to assess TREM2 agonism, including Syk phosphorylation, NFAT signaling, APOE internalization, and microglial phagocytosis.
- Pharmacokinetic profiling to evaluate solubility, metabolic stability, clearance, and safety margins (hERG).
- Functional studies in iPSC-derived microglia and neuron-microglia co-cultures to assess Aβ-induced inflammation and neuroprotection.
Main Results:
- Identification of S9 as a TREM2 small molecule agonist with 0.95 µM binding affinity.
- S9 demonstrated TREM2 agonism, enhancing microglial phagocytosis and activating downstream signaling pathways.
- S9 exhibited improved pharmacokinetic properties, including enhanced solubility, metabolic stability, and a better safety margin compared to the precursor compound.
- S9 suppressed amyloid-beta-induced IL-1β secretion in a TREM2-dependent manner and preserved synaptic integrity in co-culture models.
Conclusions:
- S9 represents the first orally bioavailable, submicromolar small molecule TREM2 agonist.
- S9 possesses favorable pharmacokinetic properties and demonstrates promising neuroprotective activity in preclinical models.
- S9 holds significant therapeutic potential for treating Alzheimer's disease by modulating TREM2 function.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:23Alzheimer Disease ll: Pathophysiology